Background: Identifying reliable predictors of long-term weight loss (LTWL) could lead to improved weight management.
O
verweight and obesity are strong and potentially modifiable risk factors for type 2 diabetes (T2D). Prevention of T2D among persons with prediabetes is a public health priority, and weight loss plays a central role in efforts to prevent or delay the disease. Whereas excess body weight is strongly associated with insulin resistance and hyperglycemia, improved glycemia is readily noticeable when persons with overweight or obesity lose weight; however, the health benefits of weight loss may last only when the initial weight loss persists over the long term (1) . There is clinical impetus to examine whether baseline demographic, psychosocial, or physiologic factors can help to identify more favorable long-term weight loss (LTWL) patterns, especially in the context of available treatments for diabetes prevention.
Randomized controlled trials (RCTs) have shown efficacy of metformin, intensive lifestyle intervention (ILS), or both in preventing or delaying onset of T2D among high-risk persons with overweight and obesity (2, 3) . In the DPP (Diabetes Prevention Program), metformin and ILS reduced risk for diabetes relative to placebo by 31% and 58%, respectively, over an average follow-up of 2.8 years (2) . Metformin and ILS were associated with average weight losses at 2.8 years of 2.1 and 5.6 kg, respectively, versus 0.1 kg with placebo (2), and weight loss was the primary driver of diabetes prevention (4, 5) . During long-term follow-up of DPP participants in its Outcomes Study (DPPOS), weight changes differed among treatment groups at 10 and 15 years (6, 7) . After achieving significantly greater initial weight loss than participants in the other groups, those in the ILS group regained about 3.5 kg over time, with a net loss of about 2 kg relative to baseline at 10 years. However, those in the metformin group achieved and maintained an average loss of about 2.5 kg, and the average weight of those in the placebo group changed by 1 kg or less during the same period (6) . The DPP and the DPPOS make up the largest and longest clinical trial of metformin for prevention of T2D. In the DPP, weight loss explained 64% of the beneficial effect of metformin on T2D risk (4) .
The primary aims of the current study were to compare differences in LTWL maintenance by original intervention group among participants who achieved clinically significant weight loss of at least 5% at 1 year and to examine baseline factors that predicted maintenance of weight loss for up to 15 years. We also evalu- 
METHODS
The DPP (July 1996 to July 2001) was an RCT that compared the efficacy of ILS, metformin, and placebo in prevention of T2D among 3234 participants with elevated glucose levels and overweight or obesity. The 1997 diagnostic criteria of the American Diabetes Association (8) were used to establish the primary outcome of diabetes, defined as a fasting plasma glucose level of 7.0 mmol/L (126 mg/dL) or higher measured semiannually or a 2-hour plasma glucose level of 11.1 mmol/L (200 mg/dL) or higher after a 75-g oral glucose load measured annually, with confirmation within 6 weeks. The protocol, baseline characteristics of the sample, and primary outcomes (including all clinical and physiologic variables examined in these analyses) have been described previously (2, 9, 10), along with minor variations in eligibility criteria.
Participants were randomly assigned to receive an individually administered ILS (a 16-session behavior modification intervention implemented over approximately 6 to 8 months, with a goal of achieving 7% weight loss through healthy dietary changes, reductions in intake of calories and fat, and 150 minutes of moderate-intensity physical activity [mostly walking] per week), metformin (850 mg twice daily), or placebo (11) . Both medication interventions were masked (double-blind), but the ILS was not. After 6 months, participants in the ILS group continued to receive individual and group reinforcement of the behavioral intervention at least every 2 months, regardless of diabetes status, but they were referred to their primary care provider (PCP) for diabetes management. Those in the metformin and placebo groups continued to receive the study drug until their plasma glucose level increased to 7.8 mmol/L (140 mg/dL) or higher, at which time use of the study drug was discontinued and diabetes management was transferred to their PCP. The DPP study protocol was modified in July 2001 after an average follow-up of 3.2 years. Participants were informed of the main results, and there was a 1-to 2-week metformin and placebo washout period to identify whether a short-term drug effect accounted for the diabetes risk reduction with metformin (12) .
The bridge protocol (1 August 2001 to 31 August 2002) was the 13-month period between the end of the DPP and the start of long-term follow-up (DPPOS). Because efficacy was established for ILS compared with metformin and placebo in the cumulative reduction in diabetes incidence during the first 3.2 years, participants in all 3 groups were offered a group-administered version of the 16-session ILS. The group intervention, which had similar content but did not include individualized problem-solving and behavior change-support components, was implemented over a 6-month period and was usually administered by the original staff. Rates of attendance at 1 or more sessions varied by group (58% in the metformin group, 40% in the ILS group, and 57% in the placebo group) (13) .
The DPPOS began in September 2002 and examined 2779 (88.5%) of the remaining DPP participants for diabetes incidence and development of diabetesrelated complications. Although the DPPOS is ongoing, the current analysis is based on average follow-up of 15 years from baseline of the DPP using data collected annually through 2013 (Appendix Figure 1 , available at Annals.org). Similar proportions of the 3 randomized DPP groups enrolled in the DPPOS (6) . During the DPPOS, metformin was provided to the group originally assigned to it, but without masking. In addition, when hemoglobin A 1c levels reached 7% or higher, use of study metformin was discontinued and diabetes care and medication management were transferred to the participant's PCP (this often included prescription of metformin by the PCP). In the ILS and placebo groups, all diabetes care and medication management were provided by the participant's PCP. Metformin use was recorded at all visits for all participants during the DPP and the DPPOS. During the DPPOS, all 3 groups were offered educational lifestyle classes 4 times per year. Twice a year, the original ILS group was offered 2 to 4 booster sessions designed to reinforce self-management behaviors for weight and activity. Lifestyle class attendance among the groups did not exceed 20% for any of the sessions offered during the DPPOS (data not shown). In all trial phases, written informed consent was obtained from all participants and studies were approved by each center's institutional review board. An independent data and safety monitoring board appointed by the study sponsor (the National Institute of Diabetes and Digestive and Kidney Diseases) oversaw the studies.
Statistical Analysis
Long-term weight loss was defined at each annual examination after the first year as weight loss of at least 5% relative to baseline. We used fixed-effects models with the assumption of normally distributed errors to estimate the percentage of weight lost over time (SAS Proc MIXED) and generalized estimating equation (GEE) models to estimate the percentage of participants with LTWL (SAS Proc GENMOD) among those who lost at least 5% in the first year (14) . The fixedeffects models used a compound symmetry correlation, and the GEE models used a logit link with an exchangeable correlation structure.
The primary aim was to evaluate baseline and postrandomization predictors of maintenance of weight loss among participants who achieved clinically significant weight loss of at least 5% at 1 year after randomization. Potential predictors of LTWL include the baseline variables listed in the Appendix Table (available at Annals.org) as well as postrandomization measures of percentage of weight lost in the first year, meeting the ILS exercise goal at the end of the core 16-session curriculum, meeting the ILS weight loss goal of 7% at theformin at the annual visit, and diabetes status at the annual visit.
Two statistical methods were used to examine predictors of LTWL. First, we used logistic regression models to evaluate potential predictors of medium-term (5 years), long-term (10 years), and very-long-term (15 years) weight loss (SAS Proc LOGISTIC). Second, we used GEE models (15, 16) to examine potential predictors of LTWL across all follow-up years. The GEE models provided an average estimate of the effect of the predictor on LTWL over the course of the study (SAS Proc GENMOD) and used a logit link and an independent correlation to ensure proper parameter estimation (17) . For both approaches, univariate models were developed separately for each predictor variable. Multivariate models included variables that were significant (P < 0.05) predictors of LTWL in the univariate analyses. Final models included only measures that remained significant in the multivariate model. Given the wide variation in the numbers of participants achieving and maintaining weight loss of at least 5% among the intervention groups, analyses were performed within groups.
The incidence of diabetes diagnosed at any time in the DPP and the DPPOS was compared between participants who did and those who did not lose at least 5% of their weight in the first year by using Cox proportional hazards models within each intervention group (SAS Proc PHREG). SAS, version 9.4 (SAS Institute), was used for all statistical analyses.
Role of the Funding Source
The National Institutes of Health, the primary study sponsor, was represented on the steering committee and contributed to study design, implementation, and publication. The funding agency was not represented in the writing group, although all members of the steering committee had input on the article's contents. All authors in the writing group had access to all data.
RESULTS

Participant Disposition
Appendix Figure 2 (available at Annals.org) shows the total number of participants randomly assigned in the DPP and those who lost at least 5% of their weight in the first year. The numbers remaining in the DPP and the DPPOS at years 5, 10, and 15 and the numbers using study-provided metformin (original metformin group only) or PCP-provided metformin among those who met the weight loss threshold are also shown. Participants discontinued study visits for various reasons, including loss to follow-up, illness, distance, and death.
Characteristics of Participants With at Least 5% Weight Loss at Year 1
Participant characteristics in each of the 3 randomized groups are shown in the Appendix Table by the amount of weight lost at year 1. A total of 289 (28.5%) participants in the metformin group, 640 (62.6%) in the ILS group, and 137 (13.4%) in the placebo group lost at least 5% of their weight in the first year. Mean weight losses at year 1 among these participants were 8.9%
(95% CI, 8.5% to 9.3%), 11.0% (CI, 10.6% to 11.4%), and 9.2% (CI, 8.3% to 10.1%), respectively.
Weight Trajectories
Figure 1 (top) shows patterns of weight change by group over the 15-year follow-up among all participants and stratified by weight loss (<5% vs. ≥5%) in the first year. Among those who lost at least 5% in year 1, mean losses relative to baseline at annual follow-up visits in years 2 to 15 ranged from 5.8% to 8.2% in the metformin group, from 3.4% to 8.9% in the ILS group, and from 1.6% to 5.8% in the placebo group. The mean losses across years 6 to 15 (after the ILS was completed and weight stabilized) relative to baseline were 6.2% (CI, 5.2% to 7.2%) in the metformin group, 3.7% (CI, 3.1% to 4.4%) in the ILS group, and 2.8% (CI, 1.3% to 4.4%) in the placebo group. The ILS group had the highest percentage (74%) of participants who lost at least 5% by year 2, but this decreased to 51% to 62% in years 3 to 5 and 41% to 47% in years 6 to 15 ( Figure 1 [bottom]). In contrast, the percentage who lost at least 5% changed from 61% at year 2 to 54% to 57% in years 3 to 5 and 51% to 64% in years 6 to 15 in the metformin group and from 49% at year 2 to 35% to 43% in years 3 to 5 and 35% to 50% in years 6 to 15 in the placebo group. The mean percentages of participants with LTWL across the 14-year follow-up among those who lost at least 5% in the first year were 56.5% (CI, 55.5% to 57.5%), 48.9% (CI, 47.9% to 49.9%), and 41.7% (CI, 40.7% to 42.7%) in the metformin, ILS, and placebo groups, respectively. The percentages for years 6 to 15 were 56.1% (CI, 55.1% to 57.1%), 43.1% (CI, 42.1% to 44.1%), and 41.9% (CI, 39.9% to 43.9%), respectively.
Predictors of LTWL
Metformin
In the metformin group, older age at baseline, higher systolic blood pressure, higher 2-hour glucose level, greater weight loss at year 1, and active use of study metformin at the time of the visit were associated with higher odds of LTWL in the univariate models. In multiply adjusted logistic and GEE models, for years 5, 10, and 15 and overall, only older age at baseline (per 10 years; odds ratios [ORs], 1.74, 2.25, 2.37, and 1.74, respectively; overall P < 0.001), greater weight loss at year 1 (per 5% loss; ORs, 2.08, 1.97, 1.14, and 1.70, respectively; overall P < 0.001), and active use of study metformin (use vs. nonuse; ORs, 4.83, 4.02, 2.17, and 1.91, respectively; overall P < 0.001) independently predicted LTWL ( Figure 2 [top]).
Intensive Lifestyle Intervention
Several measures were significant in univariate models in the ILS group. However, in multiply adjusted models, for years 5, 10, and 15 and overall, only older age at baseline (per 10 years; ORs, 2.07, 2.17, 2.03, and 2.00, respectively; overall P < 0.001) and greater weight loss at year 1 (per 5% loss; ORs, 1.83, 1.80, 1.40, and 1.59, respectively; overall P < 0.001) independently increased the odds of LTWL. Conversely, a diagnosis of diabetes during follow-up (diabetes vs. no dia-
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betes; ORs, 0.56, 0.86, 0.94, and 0.74, respectively; overall P = 0.038) and family history of diabetes (history vs. no history; ORs, 0.65, 0.66, 0.58, and 0.74, respectively; overall P = 0.051) independently decreased the odds ( Figure 2 [middle] ).
Placebo
Age at baseline did not predict LTWL in the placebo group. In univariate and multivariate models, for years 5, 10, and 15 and overall, only fasting glucose level (per 0.55 mmol/L [10 mg/dL]; ORs, 2.23, 2.08, 2.57, and 1.83, respectively; overall P = 0.002) and weight loss at year 1 (per 5% loss; ORs, 1.09, 1.48, 1.32, and 1.43, respectively; overall P = 0.001) were significant predictors ( Figure 2 [bottom] ).
Weight Loss and Diabetes Incidence
Among participants who had lost less than 5% versus at least 5% of their weight at year 1, diabetes incidence rates were 54% versus 41% for metformin (P < 0.001), 61% versus 39% for ILS (P < 0.001), and 
%
Error bars represent 95% CIs. Sample sizes were 289 at year one, 247 at year five, 236 at year ten, and 172 at year fifteen in the metformin group; 640 at year one, 540 at year five, 491 at year ten, and 373 at year fifteen in the intensive lifestyle intervention group; and 137 at year one, 110 at year five, 104 at year ten, and 92 at year fifteen in the placebo group. DPP = Diabetes Prevention Program; LTWL = long-term weight loss. Top. Observed weight loss over 15 y among all participants and those who lost <5% vs. ≥5% of their weight in the first year, by treatment group. Bottom. Observed percentages of participants with ≥5% weight loss each year in years 2 to 15 among those who lost ≥5% in the first year, by treatment group. 
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Placebo
Results are from generalized estimating equation and multiple logistic regression models predicting ≥5% weight loss overall and at 5, 10, and 15 y. Odds ratios are displayed on a logarithmic scale. Error bars represent 95% CIs. Top. Metformin group. Older age at randomization (per 10 y), greater weight loss at year 1 (per 5%), and active use of study metformin increased odds of long-term weight loss. Middle. Intensive lifestyle intervention group. Older age at randomization (per 10 y) and greater weight loss at year 1 (per 5%) increased odds of long-term weight loss, whereas current diabetes status and family history of diabetes decreased odds. Bottom. Placebo group. Greater weight loss at year 1 (per 5%) and higher fasting glucose level (per 0.55 mmol/L [10 mg/dL]) were the only predictors of long-term weight loss.
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57% versus 48% for placebo (P = 0.057) over the full 15-year follow-up.
DISCUSSION
We examined weight changes over 15 years among persons who had overweight or obesity, were at risk for T2D, were enrolled in the DPP, and continued in the DPPOS and elucidated characteristics of those achieving LTWL. Our key findings are 3-fold. First, although twice as many participants in the ILS group versus the metformin group lost at least 5% of their weight in the first year, those who were originally assigned to metformin had greater success in maintaining LTWL. Second, among the many characteristics of participants examined in this exploratory analysis, greater 1-year weight loss predicted LTWL in all groups. Other independent predictors of LTWL were older age and current use of metformin in the metformin group, older age and absence of either diabetes or a family history of diabetes in the ILS group, and baseline fasting plasma glucose level in the placebo group. Third, cumulative diabetes incidence rates over 15 years were lower among those who lost at least 5% of their weight in the first year.
A recent systematic review and meta-analysis reported average weight loss of 1.1 kg with use of metformin for varying periods (18) . In the DPP and the DPPOS, participants in the metformin group lost an average of 2.1% after 2 years and maintained weight loss of about 2% over the next 10 years (19). The current investigation builds on this by showing that approximately 30% of persons with overweight or obesity at baseline lost at least 5% over a year with metformin therapy, and more than half of this subset maintained this weight loss for as long as 15 years.
Among the drugs approved primarily for treatment of obesity, only 2 have been studied for more than 2 years in RCTs. In the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) trial (20) of 3305 patients with obesity and diabetes, orlistat was associated with weight loss of 9.6% versus 5.6% with placebo, but this difference narrowed to 3.2% versus 1.3% at 4 years, at which point significant attrition in the study sample hampered interpretation of weight changes and diabetes results. In addition, long-term adherence to orlistat is poor (21) . Liraglutide (3.0 mg/d) led to greater weight loss (6.1% vs. 1.9%) and lower cumulative diabetes incidence (2% vs. 6%) than placebo at 3 years in a large study of persons with obesity and prediabetes (22) . However, the need for daily injections and high cost are key limitations of liraglutide for longterm weight management and T2D prevention. Therefore, other interventions that could promote LTWL are needed. Metformin is attractive because most professional guidelines, including those from the American College of Physicians and the American Diabetes Association (23, 24) , recommend it as the first-line medication for patients with newly diagnosed T2D. It is inexpensive, is generally well tolerated, and is used extensively in primary care.
Metformin has several mechanisms and sites of action in humans. Its beneficial effects include inhibition of gluconeogenesis with a consequent decrease in hepatic glucose output and increased insulin sensitivity, increased glucose utilization in the gut and enhanced insulin sensitivity in skeletal muscle (25, 26) , and effects on the gut microbiota and the immune system (27). However, the mechanisms that contribute to its effects on body weight are not well understood. Decreases in appetite and food intake have been reported with metformin in several (22, 28 -30) but not all (31) studies. Metformin is not known to significantly alter energy expenditure (25, 32) . It is well recognized that the human body adapts to weight loss with compensatory neuronal, hormonal, and metabolic changes that promote weight regain (33) (34) (35) (36) . Whether metformin counters some of these compensatory changes must be further investigated.
Among participants who lost at least 5% of their weight in the first year, the degree of weight loss at year 1 predicted LTWL in each of the originally randomized groups. Several studies have reported that weight loss in the first 3 to 6 months predicts weight loss at 1 to 2 years with lifestyle interventions as well as pharmacotherapy (1, 37-40). Our findings that initial weight loss and older age are predictive of LTWL and that weight loss is largely associated with favorable diabetes and other health outcomes are consistent with prior observations in the DPP, the DPPOS, and other studies (5, 41-43). Findings of several physiologic, neurohormonal, and feeding studies that examined differences between older and younger persons suggest that aging is associated with impaired ability to accurately regulate energy balance via adjustments in energy intake (44 -49). It is unclear whether LTWL over periods as long as 15 years is associated with better or worse health outcomes overall, especially among persons in their seventh or eighth decade of life.
Of note, despite significant weight regain, participants in the ILS group who lost at least 5% of their weight in the first year still maintained average weight loss of 3.7% relative to baseline during years 6 to 15. From a population health perspective, this finding gains importance with increasing dissemination and implementation of DPP-modeled lifestyle programs (50) and reimbursement for such interventions (51, 52). The decision by Medicare to reimburse for DPPmodeled lifestyle interventions when implemented by recognized providers using standardized outcome measures has strong potential to add to the research on long-term treatment response.
The strengths of the current study include a long follow-up of 15 years in the originally randomized groups, high retention (7), and large sample sizes in the metformin and ILS groups. However, this study has several limitations. Although the DPP was an RCT, our subanalysis examining participants who lost at least 5% of their weight in the first year was a secondary analysis. Racial and ethnic minorities were well represented in our sample, but it had few unemployed or low-income participants (10) and thus may have limited generalizLong-Term Weight Loss With Metformin or Lifestyle Intervention ORIGINAL RESEARCH ability. Although retention was high, some participants discontinued participation or died over the 15-year follow-up. However, the observed effects at 5, 10, and 15 years and the average effects across the entire follow-up were consistent. Other possible predictors of LTWL were not measured in the DPP and the DPPOS. We opted for the 5% threshold to define initial weight loss as well as LTWL because this degree of weight loss confers meaningful health benefits (1), but some researchers might apply a different threshold (53). Whether the results of our analysis among persons at high risk for diabetes would transfer to those beginning T2D treatment with metformin is unknown. Finally, the LTWL we report with metformin is only for the 28.5% of participants who lost at least 5% of their weight in the first year. However, this is a sizeable proportion given that millions of persons worldwide are treated with metformin as the first-line drug for T2D. It is also important to recognize that participants in the metformin group continued use of the drug for up to 15 years, whereas in the ILS group the intervention was administered at a high intensity in the first 3 years but at a much lower intensity in later years, and although booster therapy sessions were offered, attendance was poor, reflecting the difficulty of implementing ILS beyond 1 to 3 years.
In conclusion, we found that older age and greater 1-year weight loss predicted LTWL over the next 14 years among DPP and DPPOS participants who lost at least 5% of their weight in the first year. Many other variables explored as potential predictors were not consistently associated with LTWL. Also, among participants with significant initial weight loss, those who were originally randomly assigned to metformin had greater success in maintaining LTWL than those randomly assigned to ILS with longer follow-up, especially during years 6 to 15. Future investigations should focus on whether metformin could be a useful intervention for LTWL after initial weight loss with lifestyle interventions, antiobesity drugs or devices, or bariatric surgery. 
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